Cargando…

Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with skin tropism. The entity was recently defined and the diagnosis is generally made by skin biopsies. It is necessary to apply appropriate immunohistochemistry to recognize this rare entity. There is no consensus on therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Demiröz, Ahu Senem, Demirkesen, Cuyan, Salihoğlu, Ayşe, Tüzüner, Nükhet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057751/
https://www.ncbi.nlm.nih.gov/pubmed/31752482
http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0195
_version_ 1783503729652137984
author Demiröz, Ahu Senem
Demirkesen, Cuyan
Salihoğlu, Ayşe
Tüzüner, Nükhet
author_facet Demiröz, Ahu Senem
Demirkesen, Cuyan
Salihoğlu, Ayşe
Tüzüner, Nükhet
author_sort Demiröz, Ahu Senem
collection PubMed
description Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with skin tropism. The entity was recently defined and the diagnosis is generally made by skin biopsies. It is necessary to apply appropriate immunohistochemistry to recognize this rare entity. There is no consensus on therapy and the survival rates are low. The aim of this study is to describe the clinical and histopathological features of BPDCN. We retrospectively reviewed 8 BPDCN cases of the Cerrahpaşa Medical Faculty diagnosed between 2005 and 2019. We documented the clinical findings, histopathologic diagnoses, and outcomes. The mean age of the patients was 58.7 years (range=11-86 years), and 7 patients were male. The patients presented with erythematous or purple papules, plaques, and papulonodular or nodular cutaneous lesions. Two had lymphadenomegaly at presentation. In microscopic evaluations, tumor cells infiltrated the entire dermis with a clear-cut subepidermal Grenz zone in all cases. CD4, CD56, and CD123 were the most frequently expressed immunohistochemical markers. The median follow-up of 7 cases was 14 months, ranging from 6 to 48 months. Three patients died of the disease, while 4 patients were still alive. Out of 7 patients, 5 received chemotherapy. We found that the outcomes of some patients were different from others but we did not link any distinct clinical or histopathological characteristics to these different outcomes.
format Online
Article
Text
id pubmed-7057751
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-70577512020-03-16 Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience Demiröz, Ahu Senem Demirkesen, Cuyan Salihoğlu, Ayşe Tüzüner, Nükhet Turk J Haematol Brief Report Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with skin tropism. The entity was recently defined and the diagnosis is generally made by skin biopsies. It is necessary to apply appropriate immunohistochemistry to recognize this rare entity. There is no consensus on therapy and the survival rates are low. The aim of this study is to describe the clinical and histopathological features of BPDCN. We retrospectively reviewed 8 BPDCN cases of the Cerrahpaşa Medical Faculty diagnosed between 2005 and 2019. We documented the clinical findings, histopathologic diagnoses, and outcomes. The mean age of the patients was 58.7 years (range=11-86 years), and 7 patients were male. The patients presented with erythematous or purple papules, plaques, and papulonodular or nodular cutaneous lesions. Two had lymphadenomegaly at presentation. In microscopic evaluations, tumor cells infiltrated the entire dermis with a clear-cut subepidermal Grenz zone in all cases. CD4, CD56, and CD123 were the most frequently expressed immunohistochemical markers. The median follow-up of 7 cases was 14 months, ranging from 6 to 48 months. Three patients died of the disease, while 4 patients were still alive. Out of 7 patients, 5 received chemotherapy. We found that the outcomes of some patients were different from others but we did not link any distinct clinical or histopathological characteristics to these different outcomes. Galenos Publishing 2020-03 2020-02-20 /pmc/articles/PMC7057751/ /pubmed/31752482 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0195 Text en © Copyright 2020 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Demiröz, Ahu Senem
Demirkesen, Cuyan
Salihoğlu, Ayşe
Tüzüner, Nükhet
Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
title Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
title_full Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
title_fullStr Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
title_full_unstemmed Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
title_short Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
title_sort blastic plasmacytoid dendritic cell neoplasia: a single center experience
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057751/
https://www.ncbi.nlm.nih.gov/pubmed/31752482
http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0195
work_keys_str_mv AT demirozahusenem blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience
AT demirkesencuyan blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience
AT salihogluayse blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience
AT tuzunernukhet blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience